Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …

Rituximab is a chimeric mouse/human monoclonal antibody (mAb) therapy with binding
specificity to CD20. It was the first therapeutic antibody approved for oncology patients and …

T cells expressing anti-CD19 chimeric antigen receptors (CARs) can induce complete
remissions (CRs) of diffuse large B cell lymphoma (DLBCL). The long-term durability of …

Preemptive rituximab infusions prevent relapses in immune thrombotic thrombocytopenic
purpura (iTTP) by maintaining normal ADAMTS13 activity. However, the long-term outcome …

Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have
revolutionised the treatment of B cell hematological malignancies and have become a …

The management of patients with relapsed or refractory follicular lymphoma has evolved
markedly in the last decade, with the availability of new classes of agents (phosphoinositide …

Background GP2013 is a rituximab biosimilar developed to stringent development
guidelines, including non-clinical and preclinical investigations and clinical trials in …

Importance Maintenance therapies are often considered as a therapeutic strategy in patients
with lymphoma following autologous hematopoietic cell transplantation (auto-HCT) to …

Non-Hodgkin's lymphoma (NHL) is the sixth-most common cancer in the UK, accounting for
around 13,700 new cases every year. Until the late 1990s, treatment relied on intensive …

CD38 is expressed in several types of non-Hodgkin lymphoma (NHL) and constitutes a
promising target for antibody-based therapy. Daratumumab (Darzalex) is a first-in-class anti …